Notice: This company has been marked as potentially delisted and may not be actively trading. Satsuma Pharmaceuticals (STSA) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without AuraNovember 26, 2024 | prnewswire.comSNBL’s Subsidiary Resubmits Migraine Drug ApplicationOctober 31, 2024 | markets.businessinsider.comSatsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without AuraOctober 30, 2024 | prnewswire.comAprea Therapeutics (NASDAQ:APRE) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comSatsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS DrugsOctober 8, 2024 | prnewswire.comSatsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific MeetingJune 13, 2024 | prnewswire.comSatsuma City High SchoolAugust 30, 2023 | usnews.comJapanese pharma acquires its crash-strapped Durham spin-outJune 9, 2023 | bizjournals.comJapanese pharma acquires its Durham spin-outJune 8, 2023 | bizjournals.comTrading was temporarily halted for "STSA" at 07:06 PM with a stated reason of "News pending."June 8, 2023 | marketbeat.comSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineMay 18, 2023 | finance.yahoo.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAMay 3, 2023 | marketwatch.comShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin NipponMay 1, 2023 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAApril 25, 2023 | marketwatch.comSTSA Satsuma Pharmaceuticals, Inc.April 22, 2023 | seekingalpha.comSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingApril 21, 2023 | finance.yahoo.comAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More UpsideApril 19, 2023 | msn.comSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAApril 18, 2023 | marketwatch.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. BuyoutApril 17, 2023 | benzinga.comPeninsula company bets big part of potential $221M sale on future of migraine drugApril 17, 2023 | bizjournals.comSatsuma Pharma Agrees To Be Acquired By Shin Nippon BiomedicalApril 17, 2023 | markets.businessinsider.comSatsuma Skyrockets after Acquisition by Shin NipponApril 17, 2023 | msn.comWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?April 17, 2023 | investorplace.comSNBL to Acquire Satsuma PharmaceuticalsApril 16, 2023 | finance.yahoo.comH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)March 30, 2023 | markets.businessinsider.comWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn RateMarch 30, 2023 | finance.yahoo.comMigraine drug maker seeks FDA approval and a partner as it cuts jobsMarch 29, 2023 | bizjournals.comSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsMarch 28, 2023 | finance.yahoo.com8-K: Satsuma Pharmaceuticals, Inc.February 18, 2023 | marketwatch.comSTSA.OFebruary 7, 2023 | reuters.comSatsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma ConferenceFebruary 2, 2023 | finance.yahoo.comDespite Trial Failure, Satsuma Pharma Says Its Migraine Candidate Has Potential For ApprovalDecember 28, 2022 | finance.yahoo.comSatsuma Pharmaceuticals Provides STS101 Development Program and Corporate UpdateDecember 20, 2022 | finance.yahoo.comMizuho Securities Reaffirms Their Hold Rating on Satsuma Pharmaceuticals (STSA)December 18, 2022 | markets.businessinsider.comAs Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) gains 14%, insiders who bought last year may be wishing they had bet higherNovember 30, 2022 | finance.yahoo.com10% Owner of Satsuma Pharmaceuticals Makes $106K BuyNovember 23, 2022 | benzinga.comSatsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceNovember 23, 2022 | finance.yahoo.comSatsuma Pharma Shares Nosedives After Disappointing Data From Migraine StudyNovember 22, 2022 | finance.yahoo.comSatsuma Pharmaceuticals (NASDAQ:STSA) Price Target Lowered to $3.00 at LADENBURG THALM/SH SHNovember 20, 2022 | marketbeat.com10% Owner of Satsuma Pharmaceuticals Purchased $4.39M In StockNovember 17, 2022 | benzinga.comSatsuma Pharmaceuticals 10% Owner Trades Company's StockNovember 17, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy Rating for Satsuma Pharmaceuticals: Here's What You Need To KnowNovember 15, 2022 | benzinga.comPeninsula drug maker's stock blows up after 2nd nasal migraine drug flopNovember 14, 2022 | bizjournals.comWhy Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?November 14, 2022 | investorplace.comSatsuma Pharma's migraine drug fails late-stage study, shares crashNovember 14, 2022 | reuters.comSatsuma Pharma's migraine drug fails in late-stage studyNovember 14, 2022 | reuters.comSatsuma crashes 80% as migraine therapy STS101 fails phase 3 trialNovember 14, 2022 | seekingalpha.comSatsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase 3 Trial of STS101 for the Acute Treatment of MigraineNovember 14, 2022 | finance.yahoo.comMizuho Securities Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)November 6, 2022 | markets.businessinsider.comSatsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business HighlightsNovember 4, 2022 | finance.yahoo.com Get Satsuma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. STSA Media Mentions By Week STSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STSA News Sentiment▼0.000.60▲Average Medical News Sentiment STSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STSA Articles This Week▼00▲STSA Articles Average Week Get Satsuma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies The PNC Financial Services Group News Today Truist Financial News Today M&T Bank News Today Fifth Third Bancorp News Today First Citizens BancShares News Today Huntington Bancshares News Today Regions Financial News Today KeyCorp News Today East West Bancorp News Today First Horizon News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STSA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Satsuma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
